The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Open accessAbstract
BACKGROUND In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1mut), while assessing the global safety of combination fulvestrant and palbociclib. METHODS We did a randomised, open-label, phase 3 trial in 83 hospitals in France. Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and monitored for rising bESR1mut during first-line aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1-21 of a 28-day cycle) therapy. Patients with newly present or increased bESR1mut in circulating tumour DNA and no synchronous disease progression were randomly assigned (1:1) to continue with the same therapy or to switch to fulvestrant (500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1) and palbociclib (dosing unchanged). The randomisation sequence was generated within an interactive web response system using a minimisation method (with an 80% random factor); patients were stratified according to visceral involvement (present or absent) and the time from inclusion to bESR1mut detection (<12 months or ≥12 months). The co-primary endpoints were investigator-assessed progression-free survival from random assignment, analysed in the intention-to-treat population (ie, all randomly assigned patients), and grade 3 or worse haematological adverse events in all patients. The trial is registered with Clinicaltrials.gov (NCT03079011), and is now complete. FINDINGS From March 22, 2017, to Jan 31, 2019, 1017 patients were included, of whom 279 (27%) developed a rising bESR1mut and 172 (17%) were randomly assigned to treatment: 88 to switching to fulvestrant and palbociclib and 84 patients to continuing aromatase inhibitor and palbociclib. At database lock on July 31, 2021, randomly assigned patients had a median follow-up of 35·3 months (IQR 29·2-41·4) from inclusion and 26·0 months (13·8-34·3) from random assignment. Median progression-free survival from random assignment was 11·9 months (95% CI 9·1-13·6) in the fulvestrant and palbociclib group versus 5·7 months (3·9-7·5) in the aromatase inhibitor and palbociclib group (stratified HR 0·61, 0·43-0·86; p=0·0040). The most frequent grade 3 or worse haematological adverse events were neutropenia (715 [70·3%] of 1017 patients), lymphopenia (66 [6·5%]), and thrombocytopenia (20 [2·0%]). The most common grade 3 or worse adverse events in step 2 were neutropenia (35 [41·7%] of 84 patients in the aromatase inhibitor and palbociclib group vs 39 [44·3%] of 88 patients in the fulvestrant and palbociclib group) and lymphopenia (three [3·6%] vs four [4·5%]). 31 (3·1%) patients had grade 3 or worse serious adverse events related to treatment in the overall population. Three (1·7%) of 172 patients randomly assigned had one serious adverse event in step 2: one (1·2%) grade 4 neutropenia and one (1·2%) grade 3 fatigue among 84 patients in the aromatase inhibitor and palbociclib group, and one (1·1%) grade 4 neutropenia among 88 patients in the fulvestrant and palbociclib group. One death by pulmonary embolism in step 1 was declared as being treatment related. INTERPRETATION PADA-1 is the first prospective randomised trial showing that the early therapeutic targeting of bESR1mut results in significant clinical benefit. Additionally, the original design explored in PADA-1 might help with tackling acquired resistance with new drugs in future trials. FUNDING Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Self-citationMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Self-citationPlasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Brett, J. O., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01462-3 · Cited by 414
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations
Jeselsohn, R., Bergholz, J. S., Pun, M., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Qiu, X., Buchwalter, G., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.004 · Cited by 276
Cited by
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 280
Metadata
- Authors
- Bidard, F.-C., Hardy-Bessard, A.-C., Dalenc, F., Bachelot, T., Pierga, J.-Y., de la Motte Rouge, T., Sabatier, R., Dubot, C., Frenel, J.-S., Ferrero, J. M., Ladoire, S., Levy, C., Mouret-Reynier, M.-A., Lortholary, A., Grenier, J., Chakiba, C., Stefani, L., Plaza, J. E., Clatot, F., Teixeira, L., D'Hondt, V., Vegas, H., Derbel, O., Garnier-Tixidre, C., Canon, J.-L., Pistilli, B., André, F., Arnould, L., Pradines, A., Bièche, I., Callens, C., Lemonnier, J., Berger, F., Delaloge, S., BIDARD, F.-C., PISTILLI, B., DALENC, F., BACHELOT, T., DE LA MOTTE ROUGE, T., SABATIER, R., DUBOT, C., FRENEL, J.-S., FERRERO, J.-M., LADOIRE, S., LEVY, C., MOURET-REYNIER, M.-A., HARDY-BESSARD, A.-C., LORTHOLARY, A., GRENIER, J., CHAKIBA, C., STEFANI, L., SOULIE, P., JACQUIN, J.-P., PLAZA, J. E., CLATOT, F., TEIXEIRA, L., D'HONDT, V., VEGAS, H., DERBEL, O., GARNIER TIXIDRE, C., DELBALDO, C., MOREAU, L., CHENEAU, C., PAITEL, J.-F., BERNARD-MARTY, C., SPAETH, D., GENET, D., MOULLET, I., BONICHON-LAMICHHANE, N., DEIANA, L., GREILSAMER, C., VENAT-BOUVET, L., DELECROIX, V., MELIS, A., ORFEUVRE, H., NGUYEN, S., LEGOUFFE, E., ZANNETTI, A., LE SCODAN, R., DOHOLLOU, N., DALIVOUST, P., ARSENE, O., MARQUES, N., PETIT, T., MOLLON, D., DAUBA, J., BONNIN, N., MORVAN, F., GARDNER, M., MARTI, A., LEVACHE, C.-B., LACHAIER, E., ACHILLE, M., VALMAR, C., BOUAITA, R., MEDIONI, J., FOA, C., BERNARD-MARTY, C., DEL PIANO, F., GOZY, M., ESCANDE, A., LEDUC, N., LUCAS, B., MILLE, D., AMMARGUELLAT, H., NAJEM, A., TROUBOUL, F., BARTHELEMY, P., DESCLOS, H., MAYEUR, D., LORCHEL, F., GUINET, F., LAURENTY, A.-P., BOUDRANT, A., GISSEROT, O., ALLEAUME, C., & DE GRAMONT, A.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 23
- Issue
- 11
- Pages
- 1367-1377
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4297984276
- Cited by
- 349
- References
- 16
- FWCI
- 38.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00555-1
- The paper
- Bidard, F.-C., Hardy-Bessard, A.-C., Dalenc, F., Bachelot, T., Pierga, J.-Y., de la Motte Rouge, T., Sabatier, R., Dubot, C., Frenel, J.-S., Ferrero, J. M., Ladoire, S., Levy, C., Mouret-Reynier, M.-A., Lortholary, A., Grenier, J., Chakiba, C., Stefani, L., Plaza, J. E., Clatot, F., . . . DE GRAMONT, A. (2022). Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00555-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.